ArticleStem cell research & therapy2026
Dental pulp stem cell exosomes promote angiogenesis via the PI3K/Akt signaling pathway to treat androgenetic alopecia.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular Vesicles for Androgenetic Alopecia: Current Evidence, Mechanisms, and Clinical Prospects.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAndrogenetic alopecia (AGA), the most common form of hair loss, is currently treated with pharmacological agents that often yield inconsistent results and side effects, highlighting the need for novel therapeutic approaches. This study aimed to investigate the therapeutic potential and molecular mechanisms of exosomes derived from dental pulp mesenchymal stem cells (DPSC-Exos) for AGA.
methodsWe employed a dihydrotestosterone (DHT)-induced AGA mouse model and treated groups with DPSC-Exos or minoxidil. Hair growth was assessed macroscopically and histologically. In vitro, human dermal papilla cells (DPCs) were treated with DHT and/or DPSC-Exos, with or without the PI3K inhibitor LY294002. Analyses included RNA sequencing, RT-qPCR, western blotting, immunofluorescence, and functional assays (proliferation, migration). Statistical significance was determined using Student's t-test or one-way ANOVA with appropriate post-hoc tests.
resultsDPSC-Exos significantly promoted hair regrowth, increased hair follicle density, and enhanced dermal thickness in mice, with efficacy comparable to minoxidil. Transcriptomic and protein analysis revealed DPSC-Exos activated the PI3K/Akt pathway and upregulated VEGFA, leading to perifollicular vascular network reconstruction. In vitro, DPSC-Exos rescued DHT-induced suppression of DPC proliferation, migration, and expression of hair-inductive markers (ALP, α-SMA). These effects were mediated through upregulation of pro-angiogenic factors (VEGFA, FGF2, ANGPT1) and were completely abolished by PI3K inhibition, confirming the pathway's necessity. A positive feedback loop between PI3K/Akt activation and VEGFA expression was identified.
conclusionOur findings demonstrate that DPSC-Exos promote hair regeneration by activating the PI3K/Akt-VEGFA axis, thereby restoring the follicular vascular niche and DPC function. This study positions DPSC-Exos as a promising, cell-free therapeutic strategy for AGA, with clear mechanistic foundations for future translational development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.